Workflow
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Core Viewpoint - Anixa Biosciences is advancing its breast cancer vaccine, with additional data from its Phase 1 clinical trial to be presented at the SITC 39th Annual Meeting, highlighting the collaboration with Cleveland Clinic and funding from the U.S. Department of Defense [1][5]. Group 1: Clinical Trial Details - The Phase 1 trial focuses on the alpha-lactalbumin vaccine for high-risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC [2][3]. - Initial Phase 1 data presented in December 2023 indicated no safety concerns and observed immune responses in a majority of patients [4]. Group 2: Vaccine Technology - The breast cancer vaccine utilizes α-lactalbumin, a protein that is present in certain breast cancers but absent in normal aging tissues post-lactation, to activate the immune system against emerging tumors [3][6]. - The vaccine includes an adjuvant to enhance the innate immune response, aiming to prevent tumor growth [3]. Group 3: Company Background - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program and various cancer vaccines [7]. - The company partners with renowned research institutions to develop and commercialize innovative cancer therapies [7].